Quiles Justin M, Gustafsson Åsa B
Department of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, United States.
Front Physiol. 2020 May 25;11:515. doi: 10.3389/fphys.2020.00515. eCollection 2020.
Mitochondrial dysfunction is a hallmark of cardiac pathophysiology. Defects in mitochondrial performance disrupt contractile function, overwhelm myocytes with reactive oxygen species (ROS), and transform these cellular powerhouses into pro-death organelles. Thus, quality control (QC) pathways aimed at identifying and removing damaged mitochondrial proteins, components, or entire mitochondria are crucial processes in post-mitotic cells such as cardiac myocytes. Almost all of the mitochondrial proteins are encoded by the nuclear genome and the trafficking of these nuclear-encoded proteins necessitates significant cross-talk with the cytosolic protein QC machinery to ensure that only functional proteins are delivered to the mitochondria. Within the organelle, mitochondria contain their own protein QC system consisting of chaperones and proteases. This system represents another level of QC to promote mitochondrial protein folding and prevent aggregation. If this system is overwhelmed, a conserved transcriptional response known as the mitochondrial unfolded protein response is activated to increase the expression of proteins involved in restoring mitochondrial proteostasis. If the mitochondrion is beyond repair, the entire organelle must be removed before it becomes cytotoxic and causes cellular damage. Recent evidence has also uncovered mitochondria as participants in cytosolic protein QC where misfolded cytosolic proteins can be imported and degraded inside mitochondria. However, this process also places increased pressure on mitochondrial QC pathways to ensure that the imported proteins do not cause mitochondrial dysfunction. This review is focused on discussing the pathways involved in regulating mitochondrial QC and their relationship to cellular proteostasis and mitochondrial health in the heart.
线粒体功能障碍是心脏病理生理学的一个标志。线粒体功能缺陷会破坏收缩功能,使心肌细胞充斥着活性氧(ROS),并将这些细胞动力源转变为促死亡细胞器。因此,旨在识别和清除受损线粒体蛋白、成分或整个线粒体的质量控制(QC)途径,对于心肌细胞等有丝分裂后细胞来说是至关重要的过程。几乎所有线粒体蛋白都由核基因组编码,这些核编码蛋白的运输需要与胞质蛋白质量控制机制进行大量的相互作用,以确保只有功能性蛋白被输送到线粒体。在细胞器内部,线粒体含有由伴侣蛋白和蛋白酶组成的自身蛋白质量控制体系。该体系代表了促进线粒体蛋白折叠和防止聚集的另一层次的质量控制。如果这个体系不堪重负,一种被称为线粒体未折叠蛋白反应的保守转录反应就会被激活,以增加参与恢复线粒体蛋白质稳态的蛋白表达。如果线粒体无法修复,在它变得具有细胞毒性并导致细胞损伤之前,整个细胞器必须被清除。最近的证据还揭示线粒体参与了胞质蛋白质量控制,错误折叠的胞质蛋白可被导入线粒体并在其中降解。然而,这一过程也给线粒体质量控制途径带来了更大压力,以确保导入的蛋白不会导致线粒体功能障碍。本综述着重讨论调节线粒体质量控制的相关途径及其与心脏细胞蛋白质稳态和线粒体健康的关系。